Unlike most large drug companies, Regeneron doesn’t use mergers and acquisitions to fortify its business. In fact, over its nearly 35-year history, the company has never purchased another public drug developer.
But Regeneron made an exception to a company called Checkmate Pharmaceuticals simply because the company has a drug called Vidutolimod which can activate anti-tumor T cell responses. I suspect basically it can make t cells reach tumor sites so that all the weapons from Regeneron's arsenal such as checking point inhibitors, bispecific antibodies can work.
The combination of vidutolimod and pembrolizumab had a manageable safety profile, and durable responses were observed in 25% of patients, with tumor regression in both injected and noninjected lesions, including visceral lesions.
Recall in the Direct trial, if I remember correctly, 2 out of 5 melanoma patients were still alive after five years.
From the perspective of a lay person, I didn't find the results from Regeneron's combo trial were impressive at all.
Having a partnership with DCVax-L can certainly make Regeneron's dream of becoming a leader in the new era of immuno-therapy. With DCVax-L as the center, I suspect all the ammo from Regeneron can maximize its efficacy
New Era of Immuno Oncology dealing with Solid (Hot/Cold & Agnostic ) Tumors
The complimentary synergy & expanding TRIO+ partners/combo’s ETC
At the center of that universe: NWBO + Poly ICLC (“King” of TKO’s) Complimentary Financial Partner the Modern Day Rip Van Wrinkle that juvenated mid Hudson Valley Tarrytown, NY in last 20 yrs: REGENERON is looking to REjuvenate & propeller itself into NEW ERA of Immuno Oncology
News 
Market Data 
Discover 
AI
